Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.61
OPK's Cash-to-Debt is ranked lower than
57% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. OPK: 1.61 )
Ranked among companies with meaningful Cash-to-Debt only.
OPK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.48  Med: 13.08 Max: No Debt
Current: 1.61
Equity-to-Asset 0.76
OPK's Equity-to-Asset is ranked higher than
73% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. OPK: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
OPK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.66 Max: 0.96
Current: 0.76
0.02
0.96
Piotroski F-Score: 6
Altman Z-Score: 3.97
Beneish M-Score: -1.76
WACC vs ROIC
20.02%
-0.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -6.00
OPK's Operating Margin % is ranked lower than
78% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. OPK: -6.00 )
Ranked among companies with meaningful Operating Margin % only.
OPK' s Operating Margin % Range Over the Past 10 Years
Min: -31624.44  Med: -82.69 Max: -6
Current: -6
-31624.44
-6
Net Margin % -2.05
OPK's Net Margin % is ranked lower than
75% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. OPK: -2.05 )
Ranked among companies with meaningful Net Margin % only.
OPK' s Net Margin % Range Over the Past 10 Years
Min: -31688.9  Med: -92.47 Max: -2.05
Current: -2.05
-31688.9
-2.05
ROE % -1.23
OPK's ROE % is ranked lower than
71% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. OPK: -1.23 )
Ranked among companies with meaningful ROE % only.
OPK' s ROE % Range Over the Past 10 Years
Min: -3196.93  Med: -20.87 Max: -1.23
Current: -1.23
-3196.93
-1.23
ROA % -0.90
OPK's ROA % is ranked lower than
70% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. OPK: -0.90 )
Ranked among companies with meaningful ROA % only.
OPK' s ROA % Range Over the Past 10 Years
Min: -1352.71  Med: -13.26 Max: -0.83
Current: -0.9
-1352.71
-0.83
ROC (Joel Greenblatt) % -35.32
OPK's ROC (Joel Greenblatt) % is ranked lower than
78% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. OPK: -35.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -130662.93  Med: -258.52 Max: -35.32
Current: -35.32
-130662.93
-35.32
3-Year Revenue Growth Rate 101.30
OPK's 3-Year Revenue Growth Rate is ranked higher than
98% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. OPK: 101.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OPK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -11.6 Max: 152
Current: 101.3
0
152
3-Year EPS without NRI Growth Rate -46.30
OPK's 3-Year EPS without NRI Growth Rate is ranked lower than
95% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. OPK: -46.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.4  Med: -9.3 Max: 152.4
Current: -46.3
-69.4
152.4
GuruFocus has detected 1 Warning Sign with OPKO Health Inc $OPK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPK's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OPK Guru Trades in Q1 2016

Ken Fisher 37,867 sh (+0.11%)
Paul Tudor Jones Sold Out
George Soros Sold Out
Murray Stahl 67,206 sh (-15.60%)
Mario Gabelli 100,775 sh (-30.39%)
Joel Greenblatt 30,179 sh (-74.93%)
» More
Q2 2016

OPK Guru Trades in Q2 2016

Paul Tudor Jones 27,173 sh (New)
Joel Greenblatt 267,485 sh (+786.33%)
Ken Fisher 37,826 sh (-0.11%)
Murray Stahl 66,333 sh (-1.30%)
Mario Gabelli 97,050 sh (-3.70%)
» More
Q3 2016

OPK Guru Trades in Q3 2016

Jim Simons 1,412,757 sh (New)
George Soros 59,837 sh (New)
John Burbank 12,234 sh (New)
Joel Greenblatt 535,214 sh (+100.09%)
Paul Tudor Jones 36,248 sh (+33.40%)
Ken Fisher 38,229 sh (+1.07%)
Mario Gabelli 97,050 sh (unchged)
Murray Stahl 60,179 sh (-9.28%)
» More
Q4 2016

OPK Guru Trades in Q4 2016

Ken Fisher 39,229 sh (+2.62%)
John Burbank Sold Out
Jim Simons Sold Out
George Soros Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 94,550 sh (-2.58%)
Murray Stahl 58,149 sh (-3.37%)
Joel Greenblatt 167,109 sh (-68.78%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.

Opko Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.

Top Ranked Articles about OPKO Health Inc

Weekly CEO Buys Highlights The largest insider buys of Macquarie, OPKO, New Residential Investment, Lannett and DeVry
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlights Insiders purchase shares of Macquarie, OPKO, First Bancorp
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlights Spotlight shines on OPKO and Guess?
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Top Insider Buys Highlight for Week of Jan. 6 Insiders bought shares at Opko Health and Resolute Energy
The largest insider buys this week were for OPKO Health Inc. (NASDAQ:OPK), Compass Diversified Holdings (NYSE:CODI), Acceleron Pharma Inc. (NASDAQ:XLRN) and Resolute Energy Corp. (NYSE:REN). Read more...
Weekly CEO Buys Highlight Insiders invest in Natus, OPKO, Mobile Mini, S&T Bancorp, Investors Real Estate
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
CEO Phillip Frost Buys OPKO Health Insider purchased 24,800 shares
Phillip Frost (Insider Trades), CEO, chairman and 10% owner of OPKO Health Inc. (NASDAQ:OPK), purchased 24,800 shares of the company on Oct. 10. The average price per share was $9.82, for a total transaction of $243,536. Read more...
Weekly CEO Buys: Abbott Laboratories, GE, OPKO Health Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys: Ryman Hospitality, OPKO Health, Actuant Corp. Recent insider buys from company CEOs
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight Stock purchases from QEP Resources, OPKO Health and Korn/Ferry International CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Insider Buys of More Than $100,000: Opko Health Chairman purchases 16,000 shares in company
Opko Health Inc. (NASDAQ:OPK) CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 16,000 shares on June 14 at a price of $9.01 per share. The total transaction amount was $144,160. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.17
OPK's PB Ratio is ranked higher than
64% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. OPK: 2.17 )
Ranked among companies with meaningful PB Ratio only.
OPK' s PB Ratio Range Over the Past 10 Years
Min: 1.99  Med: 8.66 Max: 800
Current: 2.17
1.99
800
PS Ratio 3.68
OPK's PS Ratio is ranked lower than
58% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. OPK: 3.68 )
Ranked among companies with meaningful PS Ratio only.
OPK' s PS Ratio Range Over the Past 10 Years
Min: 3.36  Med: 31.89 Max: 158.13
Current: 3.68
3.36
158.13
Price-to-Free-Cash-Flow 581.43
OPK's Price-to-Free-Cash-Flow is ranked lower than
98% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.25 vs. OPK: 581.43 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
OPK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 22.54  Med: 39.48 Max: 850.71
Current: 581.43
22.54
850.71
Price-to-Operating-Cash-Flow 142.81
OPK's Price-to-Operating-Cash-Flow is ranked lower than
93% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.28 vs. OPK: 142.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
OPK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 20.71  Med: 38.32 Max: 208.95
Current: 142.81
20.71
208.95
EV-to-EBIT -67.76
OPK's EV-to-EBIT is ranked lower than
99.99% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.12 vs. OPK: -67.76 )
Ranked among companies with meaningful EV-to-EBIT only.
OPK' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.8  Med: -33.9 Max: 203.7
Current: -67.76
-130.8
203.7
EV-to-EBITDA 147.07
OPK's EV-to-EBITDA is ranked lower than
96% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.99 vs. OPK: 147.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -146.6  Med: -34.3 Max: 539.9
Current: 147.07
-146.6
539.9
Current Ratio 1.84
OPK's Current Ratio is ranked lower than
61% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. OPK: 1.84 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 3.22 Max: 42.13
Current: 1.84
1.22
42.13
Quick Ratio 1.66
OPK's Quick Ratio is ranked lower than
53% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. OPK: 1.66 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.22 Max: 42.13
Current: 1.66
1.08
42.13
Days Inventory 25.39
OPK's Days Inventory is ranked higher than
93% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. OPK: 25.39 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 25.39  Med: 191.87 Max: 500.07
Current: 25.39
25.39
500.07
Days Sales Outstanding 65.82
OPK's Days Sales Outstanding is ranked higher than
59% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. OPK: 65.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 153.78 Max: 727.85
Current: 65.82
38.86
727.85
Days Payable 31.85
OPK's Days Payable is ranked lower than
84% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. OPK: 31.85 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 31.85  Med: 108.04 Max: 1499.3
Current: 31.85
31.85
1499.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.60
OPK's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. OPK: -10.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -146.3  Med: -14.4 Max: 0.4
Current: -10.6
-146.3
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.88
OPK's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
55% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. OPK: 2.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
OPK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.88  Med: 8.33 Max: 62.44
Current: 2.88
2.88
62.44
Price-to-Median-PS-Value 0.12
OPK's Price-to-Median-PS-Value is ranked higher than
99% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. OPK: 0.12 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.12 Max: 30
Current: 0.12
0.12
30
Earnings Yield (Greenblatt) % -1.48
OPK's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. OPK: -1.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.48  Med: 0.5 Max: 0.5
Current: -1.48
-1.48
0.5

More Statistics

Revenue (TTM) (Mil) $1,222
EPS (TTM) $ -0.06
Beta2.42
Short Percentage of Float24.26%
52-Week Range $7.13 - 12.15
Shares Outstanding (Mil)558.22

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 612 795 1,114
EPS ($) -0.20 0.02 0.35
EPS without NRI ($) -0.20 0.02 0.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for NAS:OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Mar 06 2017 
Weekly CEO Buys Highlight Feb 27 2017 
Weekly CEO Buys Highlights Feb 13 2017 
Weekly CEO Buys Highlights Feb 06 2017 
OPKO CEO Invests in Company Jan 30 2017 
Weekly CEO Buys Highlight Jan 22 2017 
Weekly CEO Buys Highlights Jan 09 2017 
Top Insider Buys Highlight for Week of Jan. 6 Jan 07 2017 
Weekly CEO Buys Highlights Dec 06 2016 
Weekly CEO Buys Highlight Oct 31 2016 

More From Other Websites
OPKO HEALTH, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation... Mar 23 2017
Opko Gets Orphan Status for Genetic Disorder Drug Mar 22 2017
OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological... Mar 22 2017
OPKO Health's GeneDx to have Significant Presence at ACMG 2017 Mar 14 2017
OPKO Health to Participate in the Barclays Global Healthcare Conference Mar 14 2017
Biotech's Rally in 2017 Stumbles on Pricing Concerns: Today's Research Reports on Opko Health and... Mar 09 2017
OPKO HEALTH, INC. Financials Mar 08 2017
OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest Mar 08 2017
OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological... Mar 08 2017
Opko Health subsidiary launches prenatal testing tool Mar 07 2017
OPKO Health, Inc. :OPK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
OPKO Subsidiary GenPath Women’s Health Announces the Availability of ClariTest™ Mar 07 2017
OPKO Health, Inc. :OPK-US: Earnings Analysis: 2016 By the Numbers : March 6, 2017 Mar 06 2017
OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research... Mar 03 2017
Edited Transcript of OPK earnings conference call or presentation 1-Mar-17 9:30pm GMT Mar 01 2017
OPKO Health reports 4Q loss Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)